archive-org.com » ORG » T » TECHLINKCENTER.ORG

Total: 656

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Novel Use And Method Of Rapamycin To Treat Toxic Shock | TechLink
    techlinkcenter org about staff Patent Identifier 20120252834 Status Active Categories Medical Biotechnology Rapamycin is used for prevention and treatment of toxic shock The toxic shock is induced for example by a toxin such as Staphylococcal enterotoxin A SEA Staphylococcal enterotoxin B SEB toxic shock syndrome toxin 1 TSST I streptococcal pyrogenic exotoxin A SPEA and streptococcal pyrogenic exotoxin C SPEC USPTO url http appft1 uspto gov netacgi nph Parser Sect1

    Original URL path: http://techlinkcenter.org/patents/20120252834 (2016-02-09)
    Open archived version from archive

  • Chlorine Dioxide Disinfectant for Surface or Rinse Applications | TechLink
    contact handling surfaces Chlorine dioxide routinely inactivates resistant bacterial spores and foodborne pathogens with better material compatibility than other chemical sanitizers and while minimizing hazards to the user and the environment The present technology mixes small quantities of two dry powders in water to produce aqueous chlorine dioxide on site at any concentration desired within minutes Concentrations can range from 1 10 ppm 25 100 ppm to more than 500 ppm and the chlorine dioxide can be used to clean surfaces anywhere at home or in the office in labs or in kitchen food handling environments or for use in flumes to rinse fresh produce Benefits Point of use generation of ClO2 Surface disinfectant spray rinse or immersion Easy mix chemicals for packets or tablets Customizable concentrations for myriad uses Inexpensive available chemicals Safe for human use and the environment The Opportunity Patent application is available for license Potential for collaboration with US Army Natick Contacts Laurel Halfpap CLP Senior Technology Manager Leader Biomedical Licensing Montana State University TechLink Bozeman Montana lhalfpap montana edu 406 994 2051 Technology Managers and Senior Advisors Read more about Laurel Halfpap CLP Dan Swanson CLP Senior Technology Manager Licensing Leader Montana State University TechLink

    Original URL path: http://techlinkcenter.org/summaries/chlorine-dioxide-disinfectant-surface-or-rinse-applications (2016-02-09)
    Open archived version from archive

  • Prophylactic treatment of human enterotoxigenic Escherichia coli (ETEC) | TechLink
    currently licensed ETEC vaccine in the US or the EU for prevention of Traveler s Diarrhea Until an effective vaccine is available there is a need for an effective prophylactic treatment such as passive oral administration of immunoglobulins Image Right The Technology This invention covers a pharmaceutical composition composed of milk immunoglobulin that will block the attachment of ETEC to the intestine ETEC produce disease by attaching themselves to the cells lining the small intestine and releasing a toxin that causes diarrhea and abdominal cramps If the ETEC cannot attach the disease will be prevented Also covered is a method to make the immunoglobulin by collecting ETEC antiadhesin antibodies in the milk of vaccinated domestic animals such as cows Taken as a pill or supplement the milk antibodies are capable of providing prophylactic protection against an ETEC infection Benefits Provides a prophylactic for ETEC infections a principal cause of Traveler s Diarrhea Avoids the costs side effects and drug resistance problems of antibiotic treatments A large global market exists with 631 million episodes and 775 000 deaths year Institute of Medicine 1986 United States Patent Application Publication No US 2006 0269560 and corresponding International Publication Number WO 2006 127798 are

    Original URL path: http://techlinkcenter.org/summaries/prophylactic-treatment-human-enterotoxigenic-escherichia-coli-etec (2016-02-09)
    Open archived version from archive

  • Orthogonal Arterial Catheter that minimizes kinking and sheering | TechLink
    easily be attached to the patient A gentle curve inside the hub guides and protects the tubing from kinking and shearing while reducing turbulence This leads to more accurate blood pressure monitoring A port enables easy access for blood sampling The incorporation of a luer lock or other connector can reduce problems with the fluid line even further When an arterial catheter is inserted into the femoral artery it is done at a low angle e g 40 60 degrees above the skin This angle of entry sometimes results in kinking of the cannula The end of the catheter that is connected to the monitoring equipment has also been known to sheer away resulting in loss of blood from the patient This unique design addresses these two problems The hub design of this new arterial catheter patent 6 610 045 provides a safe passageway that prevents pinching of the cannula A luer lock or other connector can secure the catheter to the monitoring equipment The lowprofile of the device reduces the chances of problems due to patient movement Additionally the design reduces blood turbulence that distorts real time blood pressure readings Benefits Reduced shearing and kinking of catheter tubing Improved

    Original URL path: http://techlinkcenter.org/summaries/orthogonal-arterial-catheter-minimizes-kinking-and-sheering (2016-02-09)
    Open archived version from archive

  • Rapid Clotting Technology | TechLink
    wounds and internal bleeding Hemorrhage is one of the most common causes of death among those who die prior to reaching an emergency room or expire in the operating room Research has demonstrated the individual effectiveness of recombinant factor VIIa and fibrinogen in clotting Factor VIIa plays a key role in activating the blood coagulation process and fibrinogen provides the raw materials needed to make an effective clot The combination of factor VIIa and fibrinogen is a logical approach to treating emergency and surgical bleeding Benefits Portable Can be used to treat trauma in the field or en route to a hospital Shelf Stable Components can be stored for years in dry form or months wet Easy to Use Reconstitutes quickly and is administered via IV Useful in Difficult Cases Able to help control bleeding in hard to reach injuries such as pelvic venous plexus tears and deep liver injuries The Opportunity Patent No 6 825 323 is available for licensing Further joint development with the Army Institute of Surgical Research is possible under a Cooperative Research and Development Agreement CRADA Additional details of the technology an overview of the licensing process and an interview with the inventor are available

    Original URL path: http://techlinkcenter.org/summaries/rapid-clotting-technology (2016-02-09)
    Open archived version from archive

  • Generation of Biomaterial Microarrays by Laser Transfer Biological Laser Printing - BioLP (TM) | TechLink
    coating layer causing the biomaterial to be propelled to a specific location on the receiving substrate The biomaterial could be proteins DNA RNA a layer of fixed or living tissue single cells etc The system is completely automated allowing for rapid accurate design of any pattern on a wide variety of substrates via CAD CAM The method can be carried out under controlled conditions of temperature air pressure humidity and sterility The spatial resolution of the deposited biomaterial can be as small as 1 micron allowing the fabrication of a microarray by dispensing tens to hundreds of picoliters of solution for each array spot and uses only a fraction of one microliter to fabricate over a thousand array spots Current proteomics experiments rely on printing techniques developed for cDNA microarrays using ink jet pin or quill arrayers that clog make air bubbles and have unnecessary sample loss problems that are solved with this technology Benefits Increases the density of deposited spots up to 100X and minimizes consumption of the biomaterial Can be used for proteins as well as other biomaterials including those in a living or active state Uses direct write to create a pattern directly on a substrate so no mask or preexisting form is needed Computer controlled precision and the ability to rapidly change between biomaterials to be deposited The Opportunity US patents 6 905 738 and 6 936 311 and patent application numbers 2004 0247777 and 2005 0018036 are available for license Prototypes have been constructed and are ready to be scaled up to make a high throughput robotic process Further joint development with the US Navy is possible under a Cooperative Research and Development Agreement CRADA Additional details of the technology an overview of the licensing process and an interview with the inventor are available through

    Original URL path: http://techlinkcenter.org/summaries/generation-biomaterial-microarrays-laser-transfer-biological-laser-printing-biolp (2016-02-09)
    Open archived version from archive

  • Readily Available, Specific, Plant Based, Endotoxin Removal Agent | TechLink
    by scientists at the Naval Research Laboratory NRL The envisioned applications include LPS removal from contaminated solutions e g pharmaceutical preparations and in vivo removal and or neutralization of LPS in septic patients Image Right The Technology The NRL team has identified PACs from multiple plant sources as a new class of LPS binding substance They have demonstrated that these PACs bind LPS with an affinity comparable to other well known LPS binding compounds such as polymyxin B PMB Further PACs appear to preferentially recognize the conserved lipid A part of LPS hence allowing the PACs to bind LPS from multiple gramnegative bacterial species Benefits Specific high removal rate of LPS with concomitant high recovery of proteins even in complex samples User friendly PACs are efficacious through a broad range of pHs 5 through 9 and ionic strengths 0 15 through 0 85 can be immobilized onto solid supports to run in either batch or column mode ideal for both in vitro LPS purification and in vivo neutralization Readily available no synthesis required PACs are found in a variety of plant materials purification method involves standard chemical procedures with relatively benign solvents Safe PACs IC50 for toxicity is 700 nM potential therapeutic candidate Regenerable treatment with 1 sodium deoxycholate The Opportunity Results reported in Anal Chem 80 2008 2113 2117 J Nat Prod 70 2007 1718 1724 Patent applications 11 832 834 Applications of the binding interaction of proanthocyanidins with bacterial and bacterial components and 11 832 852 along with their foreign filings are available for licensing Inventors may be available for consultation and collaboration Contacts Joan Wu Singel CLP Senior Technology Manager Chief Technology Scout Montana State University TechLink Bozeman Montana jwu singel montana edu 406 994 7705 Technology Managers and Senior Advisors Read more about Joan Wu Singel

    Original URL path: http://techlinkcenter.org/summaries/readily-available-specific-plant-based-endotoxin-removal-agent (2016-02-09)
    Open archived version from archive

  • Vaccine for human enterotoxigenic Escherichia coli (ETEC) | TechLink
    of Traveler s Diarrhea New vaccines against ETEC are critical especially for developing countries where diarrheal diseases are most prevalent and the medical infrastructure is limited Image Right The Technology The Navy has developed two ETEC vaccine compositions that are stable and enzyme resistant The first composition uses ETEC adhesin peptides as immunogens The second is a combination chimera of the adhesin fused to an enterotoxin that will induce antiadhesin and anti toxin antibodies that act together to protect against ETEC infection Both vaccine compositions induce antibodies that will block the attachment of ETEC to the intestinal wall and prevent ETEC from releasing a toxin that causes diarrhea and abdominal cramps Benefits Provides a vaccine for ETEC infections a principal cause of Traveler s Diarrhea Avoids the costs side effects and drug resistance problems of antibiotic treatments Large global market size with an estimated 631 million episodes and 775 000 deaths year Institute of Medicine 1986 The Opportunity Animal studies have been done United States Patent Application Publication No US 2006 0153878 and the corresponding patent applications in Canada the European Union Japan Australia and India and a related PCT application International Publication No WO 2007 114878 are available for

    Original URL path: http://techlinkcenter.org/summaries/vaccine-human-enterotoxigenic-escherichia-coli-etec (2016-02-09)
    Open archived version from archive



  •